Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA’s Cyanide Poisoning Agent Cyanokit Approved With Pivotal Animal Data

This article was originally published in The Pink Sheet Daily

Executive Summary

The product will launch in first quarter 2007, U.S. subsidiary VP-Regulatory Affairs Elliot Berger tells “The Pink Sheet” DAILY.

You may also be interested in...



Levaquin Approval For Plague Carries Just One Postmarketing Requirement

Study requirement for J&J’s antibiotic is less onerous than the studies that were imposed for the two other products approved under the Animal Rule.

Animal Rule Studies Should Be As Well-Designed As Human Clinical Trials, Panel Says

FDA's Anti-Infective Drugs Advisory Committee unanimously said ciprofloxacin and Ortho-McNeil-Janssen Pharmaceuticals Inc.’s Levaquin (levofloxacin) had proven their efficacy for pneumonic plague in studies in African Green Monkeys, but the panel may be less willing to overlook study design flaws in less life-threatening conditions.

Biomira Expands Oncology Pipeline With ProlX Acquisition

ProlX's lead agent is scheduled to enter Phase II for pancreatic cancer.

Related Content

Topics

UsernamePublicRestriction

Register

PS063592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel